Skip to main content
MLTX
NASDAQ Life Sciences

Major Shareholder BVF Partners Reduces Stake by $63 Million

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$17.24
Mkt Cap
$1.245B
52W Low
$5.95
52W High
$62.75
52W Position info
190% above low
Off High info
73% below high
Rel. Volume info
0.8× avg
Market data snapshot near publication time

MLTX has more than doubled off its 52-week low of $5.95.

Summary

BVF Partners, a significant institutional investor and affiliate of a director, reported the sale of 3.75 million shares of MoonLake Immunotherapeutics for approximately $63 million, reducing its beneficial ownership to 22.3%.


Key Events · Ownership and Investor Activity · MLTX

  • Significant Share Sale

    BVF Partners and its affiliated entities sold an aggregate of 3,750,000 Class A ordinary shares.

  • Substantial Transaction Value

    The shares were sold at a price of $16.79 per share, totaling approximately $62.96 million in proceeds.

  • Reduced Ownership Stake

    Following the sale, BVF Partners' aggregate beneficial ownership in MoonLake Immunotherapeutics decreased to 16,001,284 shares, representing approximately 22.3% of the outstanding shares.

  • Director Affiliation

    The selling entities are affiliated with Mark N. Lampert, who is a director and officer of BVF Inc., the general partner of BVF Partners L.P./IL.


Analysis · MLTX · Life Sciences

This Schedule 13D/A filing formally updates the beneficial ownership of BVF Partners and its affiliates following a significant sale of shares. The sale of 3.75 million shares for approximately $63 million represents a substantial reduction in their stake, from an implied 27.5% to 22.3% of the company. This transaction, which was previously reported in a Form 4 on April 2, 2026, and foreshadowed by a Form 144 on April 1, 2026, signals a notable decrease in conviction from a major institutional investor with ties to a company director. Such a large disposition by a significant shareholder can create an overhang on the stock and may be interpreted negatively by the market, especially for a life sciences company that recently extended its cash runway.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, MLTX was trading at $17.24 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $5.95 to $62.75. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

MLTX - Latest Insights

MLTX
Nov 09, 2026, 6:00 AM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $11.60
Real-time Price: $11.09 info
Change: -$0.510 (-4%) info
Market Cap: $948.514M info
MLTX
Nov 04, 2026, 7:10 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $11.62
Real-time Price: $11.09 info
Change: -$0.530 (-5%) info
Market Cap: $948.514M info
MLTX
Nov 04, 2026, 7:07 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $11.61
Real-time Price: $11.09 info
Change: -$0.520 (-4%) info
Market Cap: $948.514M info
MLTX
Sep 30, 2026, 4:15 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $11.81
Real-time Price: $11.09 info
Change: -$0.7207 (-6%) info
Market Cap: $948.514M info
MLTX
Aug 10, 2026, 1:21 PM EDT
Source: Benzinga
Importance Score:
7
Price at Filing: $17.11
Real-time Price: $11.09 info
Change: -$6.02 (-35%) info
Market Cap: $948.514M info